

PLEASE DISTRIBUTE TO OTHER HEALTHCARE PROFESSIONALS IN YOUR FACILITY



Pfizer Australia Pty Ltd
Level 15-18, 151 Clarence Street
Sydney, NSW, 2000

17th May 2023

Dear Healthcare Professional,

Subject: Growth Hormone Treatment Continuity

As you may know, the Therapeutic Goods Administration (TGA) recently published an anticipated shortage of a growth hormone preparation, beginning from 1 June 2023 through to 31 December 2023. You can find details of this shortage on the TGA website:

<https://apps.tga.gov.au/Prod/msi/Search/Details/somatropin>.

Shortage of this daily growth hormone preparation has impacted many countries globally and therefore placed a significant increase on demand for alternate daily growth hormone therapies. Pfizer Australia has taken steps to ensure supply reliability of GENOTROPIN[®] (somatropin) in response to the anticipated increase in demand resulting from the supply constraint of the alternate brand of daily growth hormone. However, the global nature of this situation means that Pfizer Australia is unable secure additional allocations of GENOTROPIN[®] above regular supply to meet the anticipated increase in demand in Australia in 2023.

At this stage, this constraint does not apply to NGENLA[®] (somatrogon) and we are working to secure additional allocations over the remainder of 2023, to meet demand for growth hormone treatment for the approved indications for this medicine. We will continue to keep you informed on the status of the availability of NGENLA[®].

When considering the ongoing management of your patients requiring growth hormone therapy, please be aware of the following information regarding the relevant preparations supplied by Pfizer in Australia.

GENOTROPIN[®] (somatropin) is indicated for the following conditions in **children**:

- Short stature due to decreased or failed secretion of pituitary growth hormone
- Growth disturbances associated with gonadal dysgenesis (Turner syndrome)
- Improvement of body composition and treatment of short stature associated with Prader-Willi syndrome (PWS) in paediatric patients.
- Growth disturbance in children with chronic renal insufficiency

GENOTROPIN[®] is also indicated for **adults** with severe growth hormone deficiency

GENOTROPIN[®] is administered by subcutaneous injection on 6-7 days/week in children and daily in adults. The full Product Information is available at [Genotropin | Pfizer Australia](#)

PLEASE DISTRIBUTE TO OTHER HEALTHCARE PROFESSIONALS IN YOUR FACILITY

NGENLA® (somatogon) is indicated for


- the long-term treatment of **paediatric** patients with growth disturbance due to insufficient secretion of growth hormone.

NGENLA® is administered by subcutaneous injection once weekly. The full Product Information is available at: <https://www.pfizer.com.au/our-products/product-finder/ngenla>

Alternate growth hormone preparations intended for daily administration may also be available through other manufacturers.

Please direct any medical enquiries regarding NGENLA® or GENOTROPIN® to Pfizer Medical Information on 1800 675 229.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'B Shapiro', is positioned above the printed name and title.

Dr Bryan K. Shapiro M.B.,Ch.B.,B.Sc.
Medical Lead, Rare Disease
Pfizer Australia
www.pfizer.com.au